Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease

Andreas Kompatscher, Jeroen H.F. de Baaij, Karam Aboudehen, Anke P.W.M. Hoefnagels, Peter Igarashi, René J.M. Bindels, Gertjan J.C. Veenstra, Joost G.J. Hoenderop

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Hepatocyte nuclear factor 1 homeobox B (HNF1β) is an essential transcription factor for the development and functioning of the kidney. Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney disease characterized by renal cysts and maturity-onset diabetes of the young (MODY). Moreover, these patients suffer from a severe electrolyte phenotype consisting of hypomagnesemia and hypokalemia. Until now, genes that are regulated by HNF1β are only partially known and do not fully explain the phenotype of the patients. Therefore, we performed chIP-seq in the immortalized mouse kidney cell line mpkDCT to identify HNF1β binding sites on a genome-wide scale. In total 7,421 HNF1β-binding sites were identified, including several genes involved in electrolyte transport and diabetes. A highly specific and conserved HNF1β site was identified in the promoter of Kcnj16 that encodes the potassium channel Kir5.1. Luciferase-promoter assays showed a 2.2-fold increase in Kcnj16 expression when HNF1β was present. Expression of the Hnf1β p.Lys156Glu mutant, previously identified in a patient with autosomal dominant tubulointerstitial kidney disease, did not activate Kcnj16 expression. Knockdown of Hnf1β in mpkDCT cells significantly reduced the appearance of Kcnj16 (Kir5.1) and Kcnj10 (Kir4.1) by 38% and 37%, respectively. These results were confirmed in a HNF1β renal knockout mouse which exhibited downregulation of Kcnj16, Kcnj10 and Slc12a3 transcripts in the kidney by 78%, 83% and 76%, respectively, compared to HNF1β wild-type mice. Thus, HNF1β is a transcriptional activator of Kcnj16. Hence, patients with HNF1β mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.

Original languageEnglish (US)
JournalKidney International
DOIs
StateAccepted/In press - Oct 8 2016

Fingerprint

Hepatocyte Nuclear Factor 1
Homeobox Genes
Potassium Channels
Kidney Diseases
Transcriptional Activation
Kidney
Hypokalemia
Electrolytes
Binding Sites
Phenotype
Mutation
Luciferases
Knockout Mice
Genes

Keywords

  • ADTKD-HNF1β
  • ChIP-seq
  • HNF1β
  • Hypomagnesemia
  • Kir4.1
  • Kir5.1
  • Magnesium
  • Potassium

ASJC Scopus subject areas

  • Medicine(all)
  • Nephrology

Cite this

Kompatscher, A., de Baaij, J. H. F., Aboudehen, K., Hoefnagels, A. P. W. M., Igarashi, P., Bindels, R. J. M., ... Hoenderop, J. G. J. (Accepted/In press). Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease. Kidney International. https://doi.org/10.1016/j.kint.2017.03.034

Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease. / Kompatscher, Andreas; de Baaij, Jeroen H.F.; Aboudehen, Karam; Hoefnagels, Anke P.W.M.; Igarashi, Peter; Bindels, René J.M.; Veenstra, Gertjan J.C.; Hoenderop, Joost G.J.

In: Kidney International, 08.10.2016.

Research output: Contribution to journalArticle

Kompatscher, A, de Baaij, JHF, Aboudehen, K, Hoefnagels, APWM, Igarashi, P, Bindels, RJM, Veenstra, GJC & Hoenderop, JGJ 2016, 'Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease', Kidney International. https://doi.org/10.1016/j.kint.2017.03.034
Kompatscher, Andreas ; de Baaij, Jeroen H.F. ; Aboudehen, Karam ; Hoefnagels, Anke P.W.M. ; Igarashi, Peter ; Bindels, René J.M. ; Veenstra, Gertjan J.C. ; Hoenderop, Joost G.J. / Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease. In: Kidney International. 2016.
@article{f69fecab555b47b68321214dcc9abb53,
title = "Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease",
abstract = "Hepatocyte nuclear factor 1 homeobox B (HNF1β) is an essential transcription factor for the development and functioning of the kidney. Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney disease characterized by renal cysts and maturity-onset diabetes of the young (MODY). Moreover, these patients suffer from a severe electrolyte phenotype consisting of hypomagnesemia and hypokalemia. Until now, genes that are regulated by HNF1β are only partially known and do not fully explain the phenotype of the patients. Therefore, we performed chIP-seq in the immortalized mouse kidney cell line mpkDCT to identify HNF1β binding sites on a genome-wide scale. In total 7,421 HNF1β-binding sites were identified, including several genes involved in electrolyte transport and diabetes. A highly specific and conserved HNF1β site was identified in the promoter of Kcnj16 that encodes the potassium channel Kir5.1. Luciferase-promoter assays showed a 2.2-fold increase in Kcnj16 expression when HNF1β was present. Expression of the Hnf1β p.Lys156Glu mutant, previously identified in a patient with autosomal dominant tubulointerstitial kidney disease, did not activate Kcnj16 expression. Knockdown of Hnf1β in mpkDCT cells significantly reduced the appearance of Kcnj16 (Kir5.1) and Kcnj10 (Kir4.1) by 38{\%} and 37{\%}, respectively. These results were confirmed in a HNF1β renal knockout mouse which exhibited downregulation of Kcnj16, Kcnj10 and Slc12a3 transcripts in the kidney by 78{\%}, 83{\%} and 76{\%}, respectively, compared to HNF1β wild-type mice. Thus, HNF1β is a transcriptional activator of Kcnj16. Hence, patients with HNF1β mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.",
keywords = "ADTKD-HNF1β, ChIP-seq, HNF1β, Hypomagnesemia, Kir4.1, Kir5.1, Magnesium, Potassium",
author = "Andreas Kompatscher and {de Baaij}, {Jeroen H.F.} and Karam Aboudehen and Hoefnagels, {Anke P.W.M.} and Peter Igarashi and Bindels, {Ren{\'e} J.M.} and Veenstra, {Gertjan J.C.} and Hoenderop, {Joost G.J.}",
year = "2016",
month = "10",
day = "8",
doi = "10.1016/j.kint.2017.03.034",
language = "English (US)",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Loss of transcriptional activation of the potassium channel Kir5.1 by HNF1β drives autosomal dominant tubulointerstitial kidney disease

AU - Kompatscher, Andreas

AU - de Baaij, Jeroen H.F.

AU - Aboudehen, Karam

AU - Hoefnagels, Anke P.W.M.

AU - Igarashi, Peter

AU - Bindels, René J.M.

AU - Veenstra, Gertjan J.C.

AU - Hoenderop, Joost G.J.

PY - 2016/10/8

Y1 - 2016/10/8

N2 - Hepatocyte nuclear factor 1 homeobox B (HNF1β) is an essential transcription factor for the development and functioning of the kidney. Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney disease characterized by renal cysts and maturity-onset diabetes of the young (MODY). Moreover, these patients suffer from a severe electrolyte phenotype consisting of hypomagnesemia and hypokalemia. Until now, genes that are regulated by HNF1β are only partially known and do not fully explain the phenotype of the patients. Therefore, we performed chIP-seq in the immortalized mouse kidney cell line mpkDCT to identify HNF1β binding sites on a genome-wide scale. In total 7,421 HNF1β-binding sites were identified, including several genes involved in electrolyte transport and diabetes. A highly specific and conserved HNF1β site was identified in the promoter of Kcnj16 that encodes the potassium channel Kir5.1. Luciferase-promoter assays showed a 2.2-fold increase in Kcnj16 expression when HNF1β was present. Expression of the Hnf1β p.Lys156Glu mutant, previously identified in a patient with autosomal dominant tubulointerstitial kidney disease, did not activate Kcnj16 expression. Knockdown of Hnf1β in mpkDCT cells significantly reduced the appearance of Kcnj16 (Kir5.1) and Kcnj10 (Kir4.1) by 38% and 37%, respectively. These results were confirmed in a HNF1β renal knockout mouse which exhibited downregulation of Kcnj16, Kcnj10 and Slc12a3 transcripts in the kidney by 78%, 83% and 76%, respectively, compared to HNF1β wild-type mice. Thus, HNF1β is a transcriptional activator of Kcnj16. Hence, patients with HNF1β mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.

AB - Hepatocyte nuclear factor 1 homeobox B (HNF1β) is an essential transcription factor for the development and functioning of the kidney. Mutations in HNF1β cause autosomal dominant tubulointerstitial kidney disease characterized by renal cysts and maturity-onset diabetes of the young (MODY). Moreover, these patients suffer from a severe electrolyte phenotype consisting of hypomagnesemia and hypokalemia. Until now, genes that are regulated by HNF1β are only partially known and do not fully explain the phenotype of the patients. Therefore, we performed chIP-seq in the immortalized mouse kidney cell line mpkDCT to identify HNF1β binding sites on a genome-wide scale. In total 7,421 HNF1β-binding sites were identified, including several genes involved in electrolyte transport and diabetes. A highly specific and conserved HNF1β site was identified in the promoter of Kcnj16 that encodes the potassium channel Kir5.1. Luciferase-promoter assays showed a 2.2-fold increase in Kcnj16 expression when HNF1β was present. Expression of the Hnf1β p.Lys156Glu mutant, previously identified in a patient with autosomal dominant tubulointerstitial kidney disease, did not activate Kcnj16 expression. Knockdown of Hnf1β in mpkDCT cells significantly reduced the appearance of Kcnj16 (Kir5.1) and Kcnj10 (Kir4.1) by 38% and 37%, respectively. These results were confirmed in a HNF1β renal knockout mouse which exhibited downregulation of Kcnj16, Kcnj10 and Slc12a3 transcripts in the kidney by 78%, 83% and 76%, respectively, compared to HNF1β wild-type mice. Thus, HNF1β is a transcriptional activator of Kcnj16. Hence, patients with HNF1β mutations may have reduced Kir5.1 activity in the kidney, resulting in hypokalemia and hypomagnesemia.

KW - ADTKD-HNF1β

KW - ChIP-seq

KW - HNF1β

KW - Hypomagnesemia

KW - Kir4.1

KW - Kir5.1

KW - Magnesium

KW - Potassium

UR - http://www.scopus.com/inward/record.url?scp=85019972691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019972691&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2017.03.034

DO - 10.1016/j.kint.2017.03.034

M3 - Article

JO - Kidney International

JF - Kidney International

SN - 0085-2538

ER -